I am a Senior Clinical Research Fellow in Vaccinology and Honorary Consultant at Imperial College London. I studied as an undergraduate in Medicine at Newnham College, University of Cambridge and Imperial College London, before qualifying as a junior doctor and undertaking specialist professional training in Genitourinary and HIV Medicine.
I am the clinical Principle Investigator across the diverse portfolio of vaccine studies at the Imperial NIHR Clinical Research Facility http://imperial.crf.nihr.ac.uk/. Working closely with Professor Robin Shattock in the Department of Infectious Disease, this work involves the crucial early-stage development of potential vaccines against pathogens such as HIV and chlamydia and includes first-in-man studies of potential vaccines. I also work closely with the Oxford Vaccine Group and Jenner Institute developing vaccines against diverse infections including ebola and malaria.
I hold a St. Mary’s Development Trust award for human vaccine research to investigate how T cells orchestrate the response to immunogens in the blood and secondary lymphoid tissue. This work is particularly important in helping us to design sophisticated vaccines that can induce the broadly neutralising antibody response required to protect against difficult targets such as HIV.
In 2019 I was awarded the Margaret Johnson prize by the British HIV Association for my work on influenza vaccine.
et al., 2021, Peripheral T cell lymphopenia in COVID-19: potential mechanisms and impact, Immunotherapy Advances, ISSN:2732-4303
et al., 2021, Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial, The Lancet Hiv, ISSN:2352-3018
et al., 2021, Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial, The Lancet, Vol:397, ISSN:0140-6736, Pages:1351-1362
et al., 2021, Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials, The Lancet, Vol:397, ISSN:0140-6736, Pages:881-891
et al., 2021, Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK, The Lancet, Vol:397, ISSN:0140-6736, Pages:99-111